Are Bioresorbable Stents Destined for a Comeback?
The excitement around bioresorbable stents might have calmed down considerably over the last year, but all that could change. Reva Medical, a San Diego, CA-based company is bringing the technology back into the spotlight with a recent approval. The company has received a CE mark for its Motiv bioresorbable scaffold to be used for the treatment of below-the-knee (BTK) peripheral artery disease (PAD).
The CE mark is also significant for Reva because it marks the companyâs entry into the PAD space. The company already has CE mark for its Fantom bioresorbable scaffold, which treats patients for coronary artery disease (CAD).
âFor the patients itâs potentially a huge advancement to be able to permanently delay the risk or the need for amputation and to open those arteries up so you donât have the pain and can have good blood flow,â Reggie Groves, CEO of Reva Medical, told MD+DI. âFor us itâs a tremendous opportunity to expand from our first product line in CAD to patients who have intermittent claudication.â
Groves noted the PAD market is much larger than the CAD market and represents a significant market opportunity for Reva. The company will identify over the next few months select centers to assess the productâs performance; inform future product development activities; and determine its complete commercial...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
More News: Back Pain | Cardiology | Cardiovascular | Clinical Trials | Eyes | Heart | Intermittent Claudication | Medical Devices | Pain | Peripheral Vascular Disease (PVD)